Navigation Links
Future Course of New Lethal Avian Flu Outbreak in China Can Be Predicted

LONDON, April 8, 2013 /PRNewswire/ -- Bioradar UK Ltd. and Replikins Ltd. today announced that when the full H7N9 virus genomic sequences from the first lethal and surviving human cases of the current outbreak of H7N9 are available for analysis, hopefully within a week, their Bioradar Replikins FluForecast® software will be able to determine within 24 hours the likely future course of the outbreak. FluForecast® had previously analyzed the virus genomic sequences in the 2003 SARS coronavirus outbreak and in the 2009 H1N1 influenza virus pandemic (1-4) to successfully predict their respective courses.

Furthermore, BioRadar UK Ltd. and Replikins Ltd. can produce an effective non-biologic synthetic vaccine tailored to the current H7N9 outbreak within seven days as they did with H5N1 (1). This is possible because scientists at Bioradar, UK. Ltd and its affiliate Replikins, Ltd. have discovered a genomic structure, and a technology related to virus rapid replication, infectivity, and lethality named Replikins.

The Replikins genomic technology permits:

1) The prediction of the arrival, geographic location, lethality, and the course of an infection, with an accuracy (p<0.001) recognized by the UN FAO (1)

  • The Replikins genomic software predicted the H1N1 outbreak and pandemic of 2009 by an increase in the genomic Replikin®Count in 2008, one year in advance of the pandemic, as reported by CNN's Dr. Sanjay Gupta (1-3)
  • The increase in genomic Replikins has been counted and seen by
    3D X-ray diffraction in the first real-time tracking of structural genomic changes from pre-pandemic through pandemic clinical states (1).

2) The production of tailored influenza vaccines in 7 days, by solid phase synthesis.

  • Replikins synthetic vaccines, shipped freeze dried, have been shown to be effective against H5N1 and Taura Syndrome viruses (1,2,4).
  • Replikins, Ltd. has developed both a cross-strain ReplikinsTransFlu®Vaccine and a specific H7N9 Replikins vaccine available for further testing.

Contact Samuel Bogoch Email tel 646-320-5910

1.  Nature Precedings.  Bogoch et al, doi:10.1038/npre.2012.6952.1
(see also seven additional  Nature Precedings Publications, Bogoch 2011-2012.
3. Dr. Sanjay Gupta of CNN Reports on Replikins (
4. Jackwood et al. Avian Diseases 53(4): 613‐617, 2009

This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE Replikins
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New 3-D transistors promising future chips, lighter laptops
2. Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
3. Discovery of a dark state could mean a brighter future for solar energy
4. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
5. The future of aerospace takes off in Montreal
6. Quantum dots brighten the future of lighting
7. CAS Names 2012 SciFinder® Future Leaders in Chemistry Program Participants
8. Tom Karagiannis, Ph.D. Awarded Future Fellowship by Australian Research Council (ARC)
9. Future memory
10. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics:
11. Electronics without current: Finnish team to research the future of nanoelectronics
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):